Biren Amin

Biren Amin is a managing director and senior research analyst on the healthcare equity research team covering biotechnology companies. Prior to joining Piper Sandler, Amin served as the chief financial officer and chief strategy officer at Pyramid Biosciences, a private biotechnology company, where he was responsible for investor relations, capital raising and leading business development activities including monitoring key competitors for therapeutics targeting solid tumors. Before Pyramid Biosciences, Amin served as the chief financial officer at Immuneering Corporation, a public clinical-stage oncology company. He previously spent 10 years at Jefferies Financial Group Inc. covering small and mid-cap biotechnology companies focused on oncology, central nervous system disorders, ophthalmology and rare diseases. Prior to Jefferies Financial Group Inc., Amin spent seven years in various equity research roles covering the biotechnology sector. Amin graduated from University of the Sciences with a bachelor's degree in pharmacy. He received his master's degree from Long Island University and his Master of Business Administration degree from the Leonard Stern School of New York University.

Universe Coverage

Biotechnology
ALLO	Allogene Therapeutics, Inc.
APLS	Apellis Pharmaceuticals, Inc.
ACLX	Arcellx, Inc.
BBIO	BridgeBio Pharma, Inc.
CRGX	Cargo Therapeutics, Inc.
CRBP	Corbus Pharmaceuticals Holdings, Inc.
ELEV	Elevation Oncology, Inc.
IMNM	Immunome, Inc.
OCUL	Ocular Therapeutix, Inc.
SRPT	Sarepta Therapeutics, Inc.
SLDB	Solid Biosciences Inc.
VKTX	Viking Therapeutics, Inc.